News articles about XOMA (NASDAQ:XOMA) have been trending somewhat positive recently, according to Accern Sentiment. The research group rates the sentiment of press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. XOMA earned a media sentiment score of 0.17 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 46.4487425869041 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Here are some of the news articles that may have effected Accern Sentiment’s rankings:
- It was a banner year for stocks, but not everyone shared in the wealth (bizjournals.com)
- It was a banner year for stocks, but not everyone shared in the wealth. (finance.yahoo.com)
- XOMA Strengthens Leadership Team with Appointments of Chief Business Officer and General Counsel (finance.yahoo.com)
- It was a banner year for stocks, but not everyone shared in the wealth. Here’s how Pittsburgh’s public companies fared. (bizjournals.com)
A number of equities analysts have commented on the stock. Wedbush restated a “buy” rating and issued a $33.00 price target on shares of XOMA in a research report on Tuesday, December 19th. HC Wainwright set a $38.00 price target on shares of XOMA and gave the company a “buy” rating in a research report on Thursday, December 7th. TheStreet raised shares of XOMA from an “e+” rating to a “c-” rating in a research note on Wednesday, November 29th. Finally, Zacks Investment Research raised shares of XOMA from a “hold” rating to a “strong-buy” rating and set a $33.00 target price for the company in a research note on Friday, November 10th. One analyst has rated the stock with a sell rating, one has given a hold rating, two have given a buy rating and one has given a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $34.67.
Shares of XOMA (XOMA) traded up $0.44 during midday trading on Friday, hitting $33.71. 96,614 shares of the company’s stock were exchanged, compared to its average volume of 156,332. XOMA has a one year low of $3.96 and a one year high of $37.25. The company has a market capitalization of $270.95, a P/E ratio of -10.34 and a beta of 3.17. The company has a debt-to-equity ratio of 3.53, a quick ratio of 3.45 and a current ratio of 3.45.
In other XOMA news, CEO James R. Neal sold 46,296 shares of the business’s stock in a transaction dated Wednesday, November 15th. The shares were sold at an average price of $28.24, for a total value of $1,307,399.04. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Thomas M. Burns sold 22,222 shares of the business’s stock in a transaction dated Wednesday, November 15th. The stock was sold at an average price of $28.69, for a total transaction of $637,549.18. Following the completion of the transaction, the senior vice president now directly owns 13,538 shares of the company’s stock, valued at $388,405.22. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 87,069 shares of company stock valued at $2,517,993. Insiders own 3.02% of the company’s stock.
WARNING: This news story was published by Stock Observer and is the sole property of of Stock Observer. If you are reading this news story on another site, it was stolen and republished in violation of US and international trademark and copyright law. The legal version of this news story can be viewed at https://www.thestockobserver.com/2018/01/13/xoma-xoma-earns-news-impact-rating-of-0-17.html.
XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab.
Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.